Crinetics Pharmaceuticals (CRNX) Other financing activities (2017 - 2026)

Crinetics Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• In Q1 2026, Other financing activities rose 124.0% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (up 163.19% YoY), while the FY2023 annual figure was $26000.0, down 99.45% from the prior year.
• Other financing activities for Q1 2026 stood at $9.9 million, up from -$14.6 million in the prior quarter.
• The five-year high for Other financing activities was $11.7 million in Q3 2025, with the low at -$32.9 million in Q4 2024.
• The 5-year median for Other financing activities is $2.0 million (2024), against an average of -$20866.7.
• Peak annual rise in Other financing activities reached 3022.81% in 2022, while the deepest fall reached 822.18% in 2022.
• Crinetics Pharmaceuticals' Other financing activities stood at $4.7 million in 2022, then tumbled by 327.2% to -$10.7 million in 2023, then plunged by 206.5% to -$32.9 million in 2024, then jumped by 55.66% to -$14.6 million in 2025, then surged by 168.19% to $9.9 million in 2026.
• Business Quant data shows CRNX's Other financing activities at $9.9 million in Q1 2026, -$14.6 million in Q4 2025, and $11.7 million in Q3 2025.